SyVento BioTech, a CDMO, opened its new mRNA manufacturing facility, a FlexFactory delivered by Cytiva, spanning over 7,000 m2, including lab and production areas, offices, and shared spaces. It establishes SyVento BioTech as a pioneer in the Polish market as it is the first mRNA FlexFactory in the country and the first in Europe equipped with the Historian automation system.
“We offer a one-stop-shop for our partners and clients, so they can produce new mRNA therapies from lab scale to commercial production, whether that is large batch or small, personalized batch,” said Dominik Lipka, CTO, SyVento BioTech. “Bringing this FlexFactory to Poland, the center point of Europe, makes new therapies available to patients in an efficient and high-quality way.”
The FlexFactory, an end-to-end platform, integrates technologies including encapsulation steps from Cytiva’s nanomedicines business (formerly Precision NanoSystems) and single-use consumables for filling processes, according to Lipka. In addition, the Historian automation system speeds the collection, aggregation, centralization, and archiving of manufacturing data, enabling data integrity and compliance, thereby setting a new standard for manufacturing efficiency and reliability, he added.
SyVento BioTech is planning a celebration of its GMP-certified facility in May 2025.
